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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
pembrolizumab has an effect on prolonging overall survival in patients with non-small
cell lung cancer expressing programmed death ligand-1 (PD-L1).
Study Design: Review of two randomized controlled trials and one cohort study
published in English in peer review journals.
Data Sources: Two randomized controlled trials and one cohort study, which evaluated
the efficacy of pembrolizumab on non-small cell lung cancer with PD-L1 expression
compared to chemotherapy. All studies were found in PubMed database.
Outcomes Measured: Overall survival measured by Kaplan-Meier analysis of overall
survival.
Results: Both of the RCT (Reck 2016 and Herbst 2016) showed pembrolizumab to be
statistically effective in prolonging overall survival in patients with NSCLC expressing
PD-L1 (p=0.005 and p<0.0001 respectively). Both studies showed a higher increase in
overall survival in patients treated with pembrolizumab compared to those treated with
traditional chemotherapy. In the cohort study conducted by Goldberg (2016), overall
survival was measured to be 7.7 months (95% CI). Pembrolizumab also showed to have a
positive effect on brain metastases as well.
Conclusions: All studies included in this systematic review indicate that pembrolizumab
is effective in prolonging overall survival in patients with NSCLC expressing PD-L1.
Key Words: Pembrolizumab, NSCLC, chemotherapy, PD-L1
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Introduction
Lung cancer is one of the most common cancers in the world. Symptoms typically
do not present until the disease has advanced. Lung cancer is characterized by coughing,
hemoptysis, dyspnea, chest pain, and weight loss. It is categorized into small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for 80-85%
of all lung cancer. NSCLC includes adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and other rare subtypes such as adenosquamous carcinoma and sarcomatoid
carcinoma.1 This paper evaluates two randomized controlled trials (RCT) and one cohort
study comparing the efficacy of pembrolizumab in treating NSCLC with the efficacy of
the traditional chemotherapy treatments.
In 2017, there have been 222,500 reported new cases of lung cancer and 155,870
deaths from lung cancer.2 It carries the highest mortality rate compared to other cancers,
as it is responsible for 25% of cancer deaths.2 The largest risk factor is tobacco use.
Studies have shown that an average male smoker has a 9 to 10 -fold risk for developing
lung cancer. The duration of smoking and the number of cigarettes smoked per day plays
a key role in determining the increased risk for lung cancer.3
The cost of managing lung cancer is a heavy burden for most patients. The
number of healthcare visits increase remarkably with the diagnosis of lung cancer and
patients are frequently admitted to a hospital. In a study conducted by Vera-Llonch et al.
patients with metastatic lung cancer receiving chemotherapy revealed an average of 1.5
hospital admissions, 8.9 days spent as inpatient, and 69 outpatient visits over the course
of 334 days.4 The same study revealed a total healthcare cost of $125,849 over the course
of 334 days. The total cost was broken down to reveal the following: outpatient care was
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responsible for 34% of the total cost, inpatient care was responsible for 20%,
chemotherapy was responsible for 22%, and other outpatient medications were
responsible for 24% of the total costs.
NSCLC is typically treated with surgical resection if indicated and chemotherapy.
Chemotherapy is typically combined with an active cytotoxic agent. Common drugs used
for treatment include cisplatin, carboplatin, docetaxel, and paclitaxel.5 These treatments
have shown to be effective initial treatments for NSCLC. However, these treatments may
not work in certain patients with evolving disease. Recently, research relating to targeting
specific receptor pathways has led to the development of immunomodulating drugs. In
these trials, the programmed cell death protein 1 (PD-1) pathways have been targeted as
the PD-1 receptor has shown to be an immune checkpoint inhibitor.6 When the PD-1
receptors on B and T cells bind with PD-L1 and PD-L2 ligands on tumor cells, it leads to
a suppression of T cells via a negative feedback loop.6 The tumor cells are then
unrecognized in the body’s immune response. Pembrolizumab is an IgG4 monoclonal
antibody that targets the PD-1 receptor pathway.6 The antibody binds to the PD-1
receptor on B and T cells and prevent the binding to PD-L1 ligands expressed on tumor
cells. An estimated 23-28% of all patients with NSCLC are found to have PD-L1
expression.7 Pembrolizumab may be more effective than cytotoxic chemotherapy in
prolonging overall survival for these patients.
Objective
The objective of this systematic review is to determine whether or not
pembrolizumab has an effect on prolonging overall survival in patients with non-small
cell lung cancer expressing programmed death ligand-1 (PD-L1).
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Methods
This systematic review evaluates two randomized controlled trials and one cohort
study. There were specific criteria used for the selection of these studies. The population
of the studies targeted men and women over the age of 18 years with NSCLC with PD-L1
expression. The intervention used in the studies was intravenous pembrolizumab of
various doses. The comparisons in the studies were various combination chemotherapy
treatments including carboplatin, cisplatin, pemetrexed, gemcitabine, paclitaxel, and
docetaxel. The primary outcome measured in the studies was overall survival of the
patients.
The studies were obtained via PubMed and they were selected based on relevance
to my research topic and the inclusion of patient oriented outcomes. The inclusion criteria
used during the selection of the articles were as follows: studies that were published
within the past 7 years and the inclusion of patient oriented outcomes – overall survival.
The exclusion criteria were patients under the age of 18 years old. All articles were
published in English and were published in peer-reviewed journals. Key words used to
search for the articles included pembrolizumab and non-small cell lung cancer. The
summary of statistics was reported via ARR, NNT, and p-value. The demographics and
characteristics of the included studies are outlined in Table 1.
Table 1: Demographics & Characteristics of included studies
Study

Type

# Pts

Herbst6

RCT

1034

Age
(yr)
>18

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Pt 18 years and older
with NSCLC;Previous
tx of 2 or more cycles
of platinum-doublet
chemotherapy;Tx of
tyrosine kinase
inhibitor for pt with
EGFR-sensitizing

Previous tx with PD1 checkpoint
inhibitors or
docetaxel;
Pt with active brain
metastases or
carcinomatous
meningitis;

60

Pembrolizumab 10
mg/kg IV over 30
min q 3 wks
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Reck7

RCT

305

>18

Goldberg8

Cohort

36

>18

mutation/ALK gene
rearrangement;
Eastern cooperative
Oncology Group
(EOCG) performance
status of 0 or 1;
PD-L1 expression on
at least 1% of tumor
cells
Pt 18 years and older
w/ stage IV NSCLC
w/o sensitizing EGFR
mutation or ALK
translocation; No
previous systemic
therapy for metastatic
ds; EOCG score of 0
or 1; at least 1
measurable lesion per
Response Evaluation
Criteria in Solid
Tumors (RECIST);
Life expectancy of at
least 3 months;
PD-L1 tumor
proportion score of
>50%
Pt 18 yo and older w/
stage IV melanoma or
NSCLC;
At least 1 untreated
brain metastasis
between 5mm and 20
mm;
ECOG performance
status of 0-1;
Life expectancy >3
months;
Adequate organ
function

4

Pt with autoimmune
disease that requires
systemic steroids;
Pt with interstitial
lung disease or hx of
pneumonitis that
requires systemic
steroids
Pt receiving systemic
glucocorticoids or
other
immunosuppressive
tx;
Pt w/ untreated brain
metastases;
Pt received systemic
tx for autoimmune
disease in the past 2
yrs;
Pt with interstitial
lung disease;
Pt received
glucocorticoids for
pneumonitis

1

Pembrolizumab
200 mg IV q 35
wks for 35 cycles

Pt w/ neurological sx
attributable to brain
metastasis;
Use of corticosteroids
to control
neurological sx or
perilesional edema;
Pt w/ leptomeningeal
disease or
autoimmune disease;
Previous tx of PD-1
or PD-L1 targeting
agents

12

Pembrolizumab 10
mg/kg IV q 2 wks

Outcomes
The primary outcome measured in these studies was overall survival of the
patients with non-small cell lung cancer treated with pembrolizumab. This was measured
and analyzed using the Kaplan-Meier analysis of overall survival.
Results
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In a study conducted by Reck et al., 305 patients with untreated advanced NSCLC
with PD-L1 expression were randomly assigned with either pembrolizumab or a
platinum-based chemotherapy.7 There were a total of 154 patients in the pembrolizumab
group and 151 patients in the chemotherapy group. The most common chemotherapy
regimen used was carboplatin plus pemetrexed (67 out of 151 patients). Crossover from
the chemotherapy group to the pembrolizumab group was allowed depending on disease
progression. At the end of the trial, 66 patients from the chemotherapy group had crossed
over to receive pembrolizumab after showing signs of disease progression.
At 6 months, 80.2% (95% CI, 72.9 to 85.7) of patients in the pembrolizumab
group were still alive compared to 72.4% (95% CI, 64.5 to 78.9) of overall survival in the
chemotherapy group. Patients receiving pembrolizumab had significantly longer overall
survival compared to those receiving chemotherapy by the end of the trial. The hazard
ratio for death was calculated to be 0.60 with a 95% CI, 0.41 to 0.89; P= 0.005. The NNT
calculated was 13 (see Table 2), indicating that 13 people are needed to treat in order for
1 person to have longer overall survival after 6 months of pembrolizumab.
Table 2. Efficacy in pembrolizumab in prolonging overall survival in patients with
advanced NSCLC as measured by Reck 2016
Study

Reck (2016)

Relative
benefit
increase (RBI)

Absolute
benefit
increase (ABI)

0.108

0.078

Number
needed to
treat (NNT)

13

P-value

0.005

Confidence
Interval (CI)

95% CI,
0.41 – 0.89

In another study conducted by Herbst et al., 689 patients with previously treated
NSCLC and PD-L1 expression were randomly assigned to pembrolizumab and
docetaxel.6 There were 346 patients assigned to pembrolizumab and 343 patients
assigned to docetaxel. Patients receiving pembrolizumab had longer overall survival than
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those receiving docetaxel. The median overall survival was 12.7 months (95% CI, 10.017.3) for those receiving pembrolizumab and 8.5 months (95% CI, 7.5-9.8) for those
receiving docetaxel. The 1 year overall survival was 52.3% for those receiving
pembrolizumab and 34.6% for those receiving docetaxel. The hazard ratio for
pembrolizumab 10 mg/kg vs. docetaxel was 0.61 with a 95% CI (0.49-0.75) and
p<0.0001. The NNT was calculated to be 10 (see Table 3).
Table 3. Efficacy of pembrolizumab 10 mg/kg in prolonging overall survival in
patients with advanced NSCLC as measured by Herbst 2016
Study

Herbst 2016

Relative benefit

Absolute benefit

Number needed to

increase (RBI)

increase (ABI)

treat (NNT)

0.249

0.109

10

Goldberg et al. conducted a cohort study in which they followed 18 patients with
NSCLC that were positive for PD-L1 expression and had untreated brain metastases.8
They were treated with 10 mg/kg of pembrolizumab every 2 weeks and data were
collected at 12 months. They measured brain metastases response to pembrolizumab as
well as overall survival. At 12 months, 6 out of 18 enrolled patients showed brain
metastasis response (33%; 95% CI, 14-59). Median overall survival was calculated to be
7.7 months with a 95% CI (3.5 – not reached). By the 12 month follow up, 8 patients
have died from disease progression and 1 patient died from unknown reasons. Adverse
reactions to treatments included grade II acute kidney injury via interstitial nephritis,
grade III pneumonitis, grade III colitis, and grade IV hyperkalemia. The patient with
grade III colitis discontinued treatment of pembrolizumab. There were no treatment
related deaths reported. The study is still on going and they plan on publishing more
reports as the data matures.
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Discussion
A diagnosis of lung cancer carries heavy weight considering it has the highest
mortality rate compared to other types of cancers. Although surgical resection and
combination chemotherapy treatments are effective in treatment of most lung cancers,
there still remains a population of patients with advanced disease that do not benefit from
traditional therapy. As medical research advances and alternative treatment options such
as pembrolizumab arise, patients are given the opportunity to remain hopeful and prolong
overall survival. This systematic review encompasses studies that display the therapeutic
benefits of using PD-L1 as a biomarker for therapy. These studies are also among the first
to use PD-L1 as a biomarker. The patient populations that experience therapeutic benefits
from pembrolizumab are those with advanced NSCLC who express PD-L1.
It is important to note the adverse effects related to pembrolizumab in comparison
to those related to traditional chemotherapy. In the study conducted by Reck et al.,
adverse effects related to pembrolizumab occurred in 73.4% of the patients while 90% of
those receiving chemotherapy experienced treatment related adverse effects.7 The most
common adverse effects from pembrolizumab were reported to be diarrhea, fatigue, and
pyrexia. The most common adverse effects from chemotherapy were anemia, nausea, and
fatigue. In the study conducted by Herbst et al., adverse effects related to pembrolizumab
occurred in 66% of patients receiving 10 mg/kg compared to 81% of patients receiving
docetaxel.6 In both studies, immune related adverse effects occurred more in those
receiving pembrolizumab. The most common immune related adverse effects were
hypothyroidism, pneumonitis, and hyperthyroidism. Hypothyroidism affected 8% of
those receiving pembrolizumab compared to <1% of those receiving docetaxel.
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Pneumonitis affected 4-5% of those receiving pembrolizumab compared to 2% of those
receiving docetaxel. Hyperthyroidism affected 4-6% of those receiving pembrolizumab
compared to 1% of those receiving docetaxel6.
Brain metastases occur in 10% of patients with NSCLC. 9 There is a poor outcome
for patients diagnosed with brain metastases from NSCLC. A median overall survival
length of 4 months has been shown in patients treated with whole brain radiation therapy
(WBRT). 9 The study conducted by Goldberg et al., demonstrated a positive response of
brain metastases from NSCLC from pembrolizumab with a median overall survival of 7.7
months.

8

As this is a cohort study, it does not allow for the comparison of the overall

survival value. Another limitation is the low enrolled patient numbers in the study. As
this study is ongoing, comparison of overall survival in those being treated with
pembrolizumab and those treated with WBRT should be completed.
Conclusion
Pembrolizumab shows to be effective in prolonging overall survival compared to
traditional chemotherapy in these studies. For patients who express PD-L1 with advanced
NSCLC, this could be indicated as first-line therapy. Pembrolizumab can also be used in
those who failed combination chemotherapy treatments as well. Further evaluations on
pembrolizumab’s adverse effects could be studied in the future. The studies chosen in this
systemic review indicate fewer adverse effects associated with pembrolizumab compared
to traditional chemotherapy treatments. The quality of life in those extra months of
survival is of great importance.

As pembrolizumab becomes indicated as first-line

therapy for these patients, adverse effects should continue to be monitored and studied.
For patients who express PD-L1 with advanced NSCLC with brain metastases, the
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ongoing data collection should compare median survival in patients with brain metastases
being treated by various methods such as WBRT. Further research with larger population
sizes and randomized controlled trials are needed to compare overall survival in patients
with brain metastases.
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